Moorfields Eye Hospital NHS Foundation Trust, 162 City Road
London, EC1V 2PD, United Kingdom
NCT Number: NCT03909425
The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment. The target population group is patients that have neovascular age-related macular degeneration and have had treatment with aflibercept for this condition.
This is a single-site study and does not involve any masking or treatment allocation.
Looking for future studies?
Notify Me50 year and older
All sexes
Observational
London, EC1V 2PD, United Kingdom
Treatment of this condition (neovascular age-related macular degeneration - nAMD) with aflibercept has transformed the outlook for patients with this sight-threatening disease.
In clinical practice, eye doctors commonly use a "treat and extend" approach to treatment in which the interval between aflibercept injections is gradually increased once there is nAMD disease quiescence.
It is uncertain about the ideal retinal imaging biomarkers doctors should use to define disease remission or inactivity; and therefore extend treatment intervals. Increased certainty of the ideal biomarker would also avoid stopping treatment too soon.
The scan the investigators will be performing (OCTA imaging) detects blood flow within the choroidal neovascular membrane (CNV) - the immature blood vessel network which causes nAMD. This scan is therefore a potentially powerful way of determining if the disease is active or quiescent. Disease activity on this device can be defined as a blood flow pattern which suggests an active CNV or lesion growth.
By better defining disease activity using OCTA, eye doctors would be more confident in continuing and defining a treatment plan for nAMD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 18 Months
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0, Change From Baseline in Pain Scores on the Visual Analog Scale at 6 Weeks
Moorfields Eye Hospital NHS Foundation Trust
Other
Defining Disease Activity in Neovascular Age-related Macular Degeneration With Optical Coherence Tomography Angiography - A Prospective, Imaging Study - The DANA Study
Acronym: DANA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06190093
Age-Related Macular Degeneration, Eye Diseases
Arcadia, California, United States
View Trial DetailsNCT04516278
Age-Related Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
Tucson, Arizona, United States
View Trial DetailsNCT05456828
Neovascular Age-related Macular Degeneration
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT05637255
Eye Diseases, Macular Degeneration
Brno, Czechia
View Trial Details